SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001636282-24-000018
Filing Date
2024-03-20
Accepted
2024-03-20 07:14:05
Documents
20
Period of Report
2024-05-13

Document Format Files

Seq Description Document Type Size
1 PRE 14A syre-20240320.htm   iXBRL PRE 14A 572715
6 syre-20240320_g1.jpg GRAPHIC 24936
7 syre-20240320_g2.jpg GRAPHIC 57992
8 syre-20240320_g3.jpg GRAPHIC 59111
9 syre-20240320_g4.jpg GRAPHIC 394534
10 syre-20240320_g5.jpg GRAPHIC 109093
  Complete submission text file 0001636282-24-000018.txt   2761962

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT syre-20240320.xsd EX-101.SCH 4523
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT syre-20240320_def.xml EX-101.DEF 7227
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT syre-20240320_lab.xml EX-101.LAB 9103
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT syre-20240320_pre.xml EX-101.PRE 5824
23 EXTRACTED XBRL INSTANCE DOCUMENT syre-20240320_htm.xml XML 90702
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-37722 | Film No.: 24766276
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)